rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    KURA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Kura Oncology at Jefferies Global Healthcare Conference: ziftomenib gains
      11h agoInvesting.comKURAJEF
      Kura Oncology: Refills Drive KOMZIFTI Launch, While Funding Bridge Sets The Pace (KURA)
      Nov 17Seeking AlphaKURA
      Kura Oncology CEO Troy Wilson buys $1.5M in shares
      Nov 17Investing.comKURA
      Kura Oncology: Less Than Nothing By The First Readout

      Analyst rates Kura Oncology a Sell: $5.85 fair value is below $7.43; about $72 million in quarterly burn could leave net cash negative by end-2028.

      Nov 16Seeking AlphaKURA
      Kura Oncology: JNJ's Bleximenib Is A Serious Threat, But Kura Still Has A Fighting Chance

      Analyst rates Kura Oncology a cautious Hold: $6.75 implies roughly 10% downside, balanced by 53% Q3 KOMZIFTI sales growth and combination potential.

      Nov 15Seeking AlphaKURA
      Kura Oncology to Participate in Two Investor Conferences in November
      Nov 13Yahoo FinanceKURA
      Citizens reiterates Kura Oncology stock rating on launch progress
      Nov 12Investing.comKURA
      Kura Oncology Q3 2026 slides: KOMZIFTI revenue surges 53% sequentially
      Nov 11Investing.comKURA
      Kura Oncology, Inc. Q3 2026 Earnings Call Summary
      Nov 11Yahoo FinanceKURA
      Kura Oncology Inc (KURA) (Q3 2026) Earnings Call Highlights: KOMZIFTI Revenue Surges 53% as ...

      Kura Oncology Inc (KURA) posted $13.9 million in KOMZIFTI net product revenue with prescriptions up 65% and secured up to $300 million in financing to fund its expanding oncology pipeline.

      Nov 11Yahoo FinanceKURA
      Kura Oncology Q3 Earnings Call Highlights
      Nov 11Yahoo FinanceKURA
      Kura Oncology Inc earnings beat by $0.03, revenue fell short of estimates
      Nov 10Investing.comKURA
      Kura Oncology: Q3 Earnings Snapshot
      Nov 10Yahoo FinanceKURA
      Kura Oncology (KURA) Reports Q3 Loss, Beats Revenue Estimates
      Nov 10Yahoo FinanceKURA
      Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update

      – KOMZIFTI® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% – – KOMZIFTI maintained majority share of new patient starts of the menin inhibitor class in the R/R NPM1-mutated AML market – – Eight abstracts accepted for ASH 2026, including two oral presentations on FLT3 inhibitor combinations, highlighting expanding development of ziftomenib in AML – – FDA alignment for approximately 40-patient monotherapy r

      Nov 10Yahoo FinanceKURA
      Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Nov 6Yahoo FinanceKURA
      Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026

      – Two oral presentations to feature first ziftomenib combination data with quizartinib in newly diagnosed and gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML – – Longer-term Phase 1b data for ziftomenib plus venetoclax and azacitidine in frontline AML support the ongoing Phase 3 KOMET-017 registrational study – – Exploratory analysis to evaluate ziftomenib clinical activity beyond NPM1-mutated and KMT2A-rearranged subtypes – – A total of four oral presentations and four posters to h

      Nov 4Yahoo FinanceKURA
      Kura Oncology to Report Third Quarter Financial Results on November 10
      Nov 3Yahoo FinanceKURA
      Bank of America Securities Remains a Buy on Kura Oncology (KURA)

      Tipranks Press Release.

      Oct 31The Globe and MailKURA
      Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know
      Oct 27Yahoo FinanceKURA
      Cantor Fitzgerald reiterates Kura Oncology stock rating at Overweight
      Oct 14Investing.comKURA
      Citizens reiterates Kura Oncology stock rating on diabetes data
      Oct 14Investing.comKURA
      Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes - Slideshow (NASDAQ:KURA) 2026-10-13
      Oct 14Seeking AlphaKURA
      Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor
      Oct 14Yahoo FinanceKURA
      Caspian Therapeutics and Kura Oncology to host investor call By Investing.com
      Oct 7Investing.comKURA
      UBS reiterates Kura Oncology stock rating on strong launch metrics
      Oct 5Investing.comKURA
      Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Oct 2Yahoo FinanceKURA
      Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and AbbVie (ABBV)

      Detailed price information for Kura Oncology (KURA-Q) from The Globe and Mail including charting and trades.

      Oct 2The Globe and MailKURA
      This biotech making precision medicines for cancer could nearly triple, says JPMorgan

      Kura Oncology's pipeline of drugs show promise for the biotech stock.

      Oct 1CNBCKURAJPM
      JPMorgan initiates Kura Oncology stock with overweight rating
      Oct 1Investing.comKURA
      JPMorgan Initiates Kura Oncology at Overweight With $30 Price Target
      Oct 1Yahoo FinanceKURA
      Kura Oncology CCO Brian Powl sells over $345k in company stock
      Sep 30Investing.comKURA
      Kura Oncology SVP sells $48,360 of stock
      Sep 30Investing.comKURA
      Kura Oncology chief legal officer sells $88,618 in shares
      Sep 30Investing.comKURA
      Kura Oncology COO Kathleen Ford sells $111,930 in company stock
      Sep 30Investing.comKURAF
      Kura Oncology CMO Mollie Leoni reports $440,236 stock sales
      Sep 30Investing.comKURA
      Kura Oncology Q2 2026 Earnings Call Transcript
      Sep 17BenzingaKURA
      Kura Oncology at Morgan Stanley conference: early sales, bigger bets
      Sep 16Investing.comKURAMS
      Kura Oncology at cantor conference: rapid launch, wider ambitions
      Sep 9Investing.comKURA
      Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary

      Kura Oncology, Inc. (NASDAQ:KURA) on Wednesday announced $50 million financing tied to advancing its menin-inhibition strategy. Launches Caspian Therapeutics With $50 Million Financing Kura said it is launching Caspian Therapeutics alongside a $50 million financing led by BVF Partners, with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Co. (NYSE:LLY), Kura Oncology, members of Kura’s leadership team, and other investors. The stated goal is to advance the company’s work in meni

      Sep 9Yahoo FinanceKURA
      Kura Oncology Appoints Jennifer Fulk as New CFO

      Detailed price information for Kura Oncology (KURA-Q) from The Globe and Mail including charting and trades.

      Sep 9The Globe and MailKURA
      Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

      – $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful biotech entrepreneurs – – Preclinical studies with KO-7246 demonstrate selective expansion of pancreatic β cells, increased endogenous insulin production, and improved glycemic control across multiple models of Type 1 and Type 2 diabetes – – Preclinical data supporting KO-7246 selected for oral pres

      Sep 9Yahoo FinanceKURA
      Kura spins diabetes work into a Lilly-backed biotech startup

      Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.

      Sep 9Yahoo FinanceKURA
      Kura Oncology at Wells Fargo conference: launch gains and pipeline breadth
      Sep 8Investing.comKURAWFC
      Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

      – Seasoned public company CFO with deep biopharmaceutical finance experience across commercial operations, R&D portfolio management, investor relations, and capital allocation – SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced the appointment of Jennifer Fulk as Chief Financial Officer, effective September 8, 2026. Ms. Fulk will join Kura’s senior leade

      Sep 8Yahoo FinanceKURA
      Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on September 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 48,450 shares of common stock to four (4) new employees under the Company’s 2023 Inducement Option

      Sep 4Yahoo FinanceKURA
      Kura Oncology (KURA) Stock Looks Fully Priced After Its 56% Run

      Kura Oncology stock has delivered a solid 55.5% return over the past year, yet on broad valuation checks it still screens as expensive rather than a clear bargain. For investors, that combination of strong recent gains and a low value score raises questions about how much good news is already reflected in the current share price. The 55.5% 1 year gain highlights how strongly sentiment has improved toward Kura Oncology, which can leave less room for disappointment if expectations...

      Sep 2Yahoo FinanceKURA
      Kura Oncology to Participate in Three Investor Conferences in September

      SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences: Wells Fargo Healthcare ConferenceSeptember 8, 20263:45 p.m. ET / 12:45 p.m. PT Cantor Global Healthcare ConferenceSeptember 9, 20269:10 a.m. ET / 6:10 a.m. PT Morgan Stanley Global Healthcare Conference September 16, 20267:45 a.m. ET / 4:45 a.m.

      Sep 1Yahoo FinanceKURA
      Kura Oncology (KURA) Receives a Buy from Mizuho Securities

      Detailed price information for Kura Oncology (KURA-Q) from The Globe and Mail including charting and trades.

      Sep 1The Globe and MailKURA
      KURA Stock Gains 37.6% in a Month: Here's What You Need to Know

      Kura's rising Komzifti sales, promising AML data and pipeline catalysts boost investor confidence and fuel KURA's gains.

      Sep 1Yahoo FinanceKURA

      This is the newest page. Registered accounts read further back.